Navigation Links
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Date:1/9/2012

THE WOODLANDS, Texas, Jan. 9, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl peptidase 4 (DPP-4) inhibitor, sitagliptin (Januvia®), one of the most widely prescribed diabetes drugs.

"The results of this study are important given that combination therapy is the mainstay of current diabetes treatment," said Dr. Pablo Lapuerta, senior vice president of clinical development and chief medical officer at Lexicon.  "Alone, LX4211 produces rapid improvement in postprandial blood glucose by delaying intestinal glucose absorption and increasing urinary glucose excretion.  When combined, the two agents produce enhanced benefits on blood glucose, insulin, GLP-1 and PYY relative to sitagliptin alone, suggesting these agents work together and could provide additional benefits for patients with type 2 diabetes."

Results from the study in 18 patients with type 2 diabetes showed that single doses of LX4211, a dual inhibitor of SGLT1 and SGLT2, in combination with sitagliptin, produced lower blood glucose levels after meals (postprandial) as compared to treatment with sitagliptin alone (p=0.012).  This enhanced glycemic control was associated with an elevation of active glucagon-like peptide-1 (GLP-1) over treatment with either LX4211 or sitagliptin alone (p<0.001).  Consistent with LX4211 monotherapy effects, LX4211 increased total GLP-1 (p<0.001) and PYY (p=0.014) with reduced insulin levels (p=0.025) when dosed with sitagliptin, all three effects not observed with sitagli
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
2. LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
3. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
4. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
5. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. CryoLife Enhances Management Team with Promotions
10. BSGI/MBI Enhances Pre-Surgical Planning For Patients With Newly Diagnosed Breast Cancer
11. Vermillion Enhances Management Team With A Key Addition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... EAST SETAUKET, N.Y., Aug. 12 Lixte,Biotechnology Holdings, ... had filed a patent application for the use ... brain tumors as potential treatments for,neurodegenerative diseases including ... Kovach, President and CEO of Lixte, said, "Lixte ...
... DIEGO, Aug. 12 MabVax Therapeutics, Inc., ... focused,on the development and commercialization of novel ... the completion of two separate,licensing agreements with ... Cancer Research (SKI)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... statement of CEO Nancy Brown on the Senate passage of ... today by the American Heart Association: , , The ... ensure a healthier future for our children with passage of ... legislation will allow us to protect them from a dirty ...
... Senators Vote for Historic Bill to Regulate Tobacco Products ... for Tobacco-Free Kids applauds U.S. Senator Richard Durbin for leading ... that gives the U.S. Food and Drug Administration (FDA) authority ... on tobacco marketing and sales to kids. , , ...
... June 11 The Campaign for Tobacco-Free Kids ... in the U.S. Senate to pass historic legislation that gives ... tobacco products, including the authority to crack down on tobacco ... the bipartisan bill 79 to 17. The House has ...
... Scheduled for Friday, June 12, 2009 , , LANCASTER, ... ) today reported financial results for the third quarter ended May ... the thirteen weeks ended May 3, 2009 were approximately $41.8 million, ... ended May 4, 2008. , , Income from continuing operations ...
... DALLAS, June 11 Zix Corporation (ZixCorp(R)), ... encryption services and payor sponsored e-Prescribing services, announced today ... assist ZixCorp,s Board of Directors in investigating strategic alternatives ... This strategic review may result in a partnership, ...
... Calif., June 11 Bionovo, Inc. (Nasdaq: BNVI ... 10, 2009 has denied all claims against the company and ... , The decision was in reference to a suit ... fraud, negligent misrepresentation and breach of oral contract stemming from ...
Cached Medicine News:Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 3Health News:Senator Reid Leads Fight to Protect America's Kids From Tobacco 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 3Health News:Herley Industries, Inc. Reports Third Quarter Earnings 4Health News:Herley Industries, Inc. Reports Third Quarter Earnings 5Health News:Herley Industries, Inc. Reports Third Quarter Earnings 6Health News:Herley Industries, Inc. Reports Third Quarter Earnings 7Health News:Herley Industries, Inc. Reports Third Quarter Earnings 8Health News:Herley Industries, Inc. Reports Third Quarter Earnings 9Health News:Herley Industries, Inc. Reports Third Quarter Earnings 10Health News:Herley Industries, Inc. Reports Third Quarter Earnings 11Health News:Herley Industries, Inc. Reports Third Quarter Earnings 12Health News:Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business 2Health News:Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied 2
Stab incision blades color coded for simple and accurate identification...
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
30, 6.0mm from end...
Medicine Products: